Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain
NCT07408193Phase 1Recruiting
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic cancer-related pain comparing Lidocaine and Ketamine Infusion with Active Placebo (Midazolam) Infusion (2 arms). Primary endpoint: Change from Baseline in the Worst Pain During the Last 24 Hours on an 11-Point Numerical Rating Scale. Started Mar 2026; status: recruiting.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrineketamine
03
Conditions
chronic cancer-related pain
Beyond the preview
Go deeper on NCT07408193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408193.